deltatrials
Completed PHASE2 NCT00057798

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Molecular And Genetic Changes In Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Vinorelbine And Gemcitabine - Phase II Study

Sponsor: Roswell Park Cancer Institute

Conditions Lung Cancer
Interventions conventional surgery cytogenetic analysis gemcitabine hydrochloride loss of heterozygosity analysis microarray analysis neoadjuvant therapy vinorelbine ditartrate
Updated 6 times since 2017 Last updated: Mar 7, 2011 Started: Mar 31, 2000 Primary completion: May 31, 2003 Completion: Jun 30, 2008

This PHASE2 trial investigates Lung Cancer and is currently completed. Roswell Park Cancer Institute leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roswell Park Cancer Institute
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Buffalo, United States